Please use this identifier to cite or link to this item:
|Title:||Glioblastoma Therapy with Substance P labelled with Bismuth-213|
|Authors:||KROLICKI Leszek; KUNIKOWSKA Jolanta; KOZIARA H; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; JAKUCINSKI M; PAWLAK Dariusz; MIKOŁAJCZAK Renata; KROLICKI B; BARSZCZ Slawomir|
|Citation:||World Journal of Nuclear Medicine vol. 12 no. Supplement 1 p. 22-23|
|Type:||Articles in periodicals and books|
|Abstract:||Gliomas are the most frequent primary brain tumors in adult patients. The most malignant of them – glioblastoma multiforme (GBM), is characterized by the worst prognosis with a median survival of 15 months. The infiltrating character of the tumor, molecular heterogeneity, as well as the protective effects of blood-brain barrier are the main causes of insufficient front line treatments (surgery, radio and chemotherapy); 90% of patients have a recurrence at the original tumor location. Therefore a new type of treatment strategies is urgently needed. Because the majority of recurrences occur within 2 cm of the resection margin, local therapies are currently under investigation. Riva P et al. in 1995 have proposed local treatment of malignant gliomas (1). This method allows for a higher concentration of drug into the tumor and omitting the blood-brain barrier. This method is also suitable for local administration of radiopharmaceuticals. Different types of biologically active ligands and radioisotopes were used.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.